Latest Oncology News

Page 2 of 33
ImpediMed lifted quarterly revenue and recurring revenue, but weaker-than-expected BCRL sales and a near-total sales team rebuild have put its path to cash-flow break-even under pressure. The company ended September with $11.6 million in cash and 4.7 quarters of funding at the quarter’s operating burn.
Ada Torres
Ada Torres
30 Oct 2026
Amplia Therapeutics is preparing the next stage of narmafotinib’s pancreatic cancer development as its ACCENT trial nears completion and a Lilly collaboration broadens the drug’s potential into lung cancer. The biotech ended September with $20.8 million in cash, rising to $25.6 million pro forma after an October R&D tax refund.
Victor Sage
Victor Sage
28 Oct 2026
OncoSil Medical delivered sharper commercial growth and a string of regulatory milestones in FY26, but the oncology device company remains heavily loss-making and dependent on future sales or fresh capital. Revenue rose 44% to $1.68 million while operating cash outflow reached $10.47 million.
Victor Sage
Victor Sage
27 Oct 2026
Immutep’s pivotal TACTI-004 lung cancer trial dominates a difficult FY26, with the failure widening the loss to A$79.3 million and triggering an impairment, cost cuts and a root cause review. The biotech retains A$68.9 million in cash, cash equivalents and term deposits, while its remaining investment case rests on IMP761 and selected efti studies.
Ada Torres
Ada Torres
27 Oct 2026
Arovella has moved its off-the-shelf CAR-iNKT therapy ALA-101 into human testing, dosing the first patient in the phase 1 SAPPHIRE trial. The study will now test safety and early signs of activity, with initial data expected in early 2027.
Ada Torres
Ada Torres
27 Oct 2026
Argent BioPharma ended the September quarter with just A$11,000 in cash after A$734,000 of operating outflows, despite retaining A$7.4 million of unused convertible financing capacity. The company is simultaneously expanding its commercial portfolio through NLC antiviral rights and a CannEpil veterinary programme.
Victor Sage
Victor Sage
23 Oct 2026
Amplia Therapeutics has received an A$4.78 million refundable R&D tax rebate, giving the clinical-stage biotechnology company additional cash to advance its FAK inhibitor programs. The funds will support multiple narmafotinib trials and related research, including studies involving Lilly.
Victor Sage
Victor Sage
22 Oct 2026
Starpharma has submitted its European trial application for DEP HER2-Lu and completed manufacture of clinical material, bringing its lead radiopharmaceutical closer to first patient dosing. The biotech also took control of Petalion, collected a Radiopharm option fee and finished the quarter with AUD $34.4 million in cash.
Ada Torres
Ada Torres
22 Oct 2026
Racura Oncology says both Phase 1 RC220 programs have cleared their opening dose cohorts without dose-limiting toxicities, while its Korean expansion broadens the CPACS trial. The company ended September with $30.7 million in cash, which management says funds committed activities into mid-2028.
Victor Sage
Victor Sage
22 Oct 2026
Invion has secured two financing arrangements that could cover up to approximately 85% of its clinical trial costs, providing support for its skin cancer and planned anogenital cancer programs. The funding comes with potential dilution, 16% interest and conditions that leave the actual amount available dependent on drawdowns and R&D tax refunds.
Victor Sage
Victor Sage
21 Oct 2026
Percheron Therapeutics has secured a funded path towards a Vanderbilt Health-led HMBD-002 trial in high-risk AML and MDS, while ending September with $4.875 million in cash. The biotechnology company also installed a new chief executive and began a preclinical combination study with Invion.
Ada Torres
Ada Torres
20 Oct 2026
Nyrada has moved its PROTECT-MI heart-attack trial into active recruitment, with four hospitals open and three patients dosed. The biotech also reported supportive US FDA feedback, encouraging preclinical oncology data and AU$13.72 million in cash after a AU$12 million placement.
Ada Torres
Ada Torres
19 Oct 2026

Browse the archive

Full archive